Brief: Oncolytics Biotech® Provides Updated Clinical Safety Data For Pelareorep, Including Across Multiple Gastrointestinal Tumors
Sept 2 (Reuters) - Oncolytics Biotech Inc ONYN.BE: ONCOLYTICS BIOTECH® PROVIDES UPDATED CLINICAL SAFETY DATA FOR PELAREOREP, INCLUDING ACROSS MULTIPLE GASTROINTESTINAL TUMORS ONCOLYTICS BIOTECH INC - FAVORABLE SAFETY PROFILE FOR PELAREOREP ACROSS MULTIPLE INDICATIONS ONCOLYTICS BIOTECH INC - INTRAVENOUSLY ADMINISTERED PELAREOREP CONTINUES TO SHOWS CLINICAL BENEFIT Source text: ID:nCNW4ld3Pa Further company coverage: ONYN.BE ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer